Niagara Falls, NY – June 14, 2024 (GLOBE NEWSWIRE) – Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce its membership in the national alliance “Cardiac PET Industry Coalition” (CPIC), an organization at the forefront of quality of patient care, advocacy and innovation to advance the field of cardiovascular PET imaging.
Positron joins forces with the coalitions founding members, Bracco Diagnostics, CDL Nuclear Technologies and Siemens Healthcare who have come together to promote federal policies that advance health outcomes for patients with cardiovascular disease and improve the availability of cardiac PET diagnostics throughout the United States.
The CPIC will be a leading advocate for fair and transparent coverage and reimbursement policies that facilitate access to cardiac PET, align practitioners with regard to research opportunities, highlight the clinical and economic benefit of the modality, and provide expanded opportunities to educate healthcare providers and policymakers on the overall value of cardiac PET. CPIC has begun its work by weighing in on 2024 final payment rules, engaging with stakeholders in the cardiac community, and developing a 2024 policy agenda.
Adel Abdullah, President of Positron stated: “Positron welcomed the opportunity to join the coalition, and personally, and I am honored to be part of current and future CPIC committees focused on the education, availability and advancement of the PET modality for cardiac studies. We believe Positron’s PET/PET-CT technology and ability to deliver the best value in the industry will play a key role in the adoption and growth of cardiac PET. Positron and our team will support and serve the coalition as best as possible for the future of the industry, concluded Mr. Abdullah.”
Cardiac PET Industry Coalition
CPIC passionately advocates for and protects the reimbursement of Cardiac PET, ensuring equitable access to innovative and life-saving technologies for healthcare providers and patients.
Comments